Gene found that is essential to maintaining breast and cancer stem cells

May 11, 2015, Medical College of Georgia
Gene found that is essential to maintaining breast and cancer stem cells
Dr. Muthusamy Thangaraju, biochemist at the Medical College of Georgia at Georgia Regents University and corresponding author of the study in the journal Nature Communications Credit: Phil Jones

The gene and hormone soup that enables women to breastfeed their newborns also can be a recipe for breast cancer, particularly when the first pregnancy is after age 30.

Researchers have now found that the gene DNMT1 is essential to maintaining breast, or mammary, , that enable normal rapid growth of the breasts during , as well as the that may enable breast cancer. They've learned that the DNMT1 gene also is highly expressed in the most common types of breast cancer.

Conversely, ISL1 gene, a tumor suppressor and natural control mechanism for stem cells, is nearly silent in the breasts during pregnancy as well as cancer, said Dr. Muthusamy Thangaraju, biochemist at the Medical College of Georgia at Georgia Regents University and corresponding author of the study in the journal Nature Communications.

"DNMT1 directly regulates ISL1," Thangaraju said. "If the DNMT1 expression is high, this ISL1 gene is low." They first made the connection when they knocked out DNMT1 in a mouse and noted the increase in ISL1. Then they got busy looking at what happened in human .

They found ISL1 is silent in most human breast cancers and that restoring higher levels to the human breast cancer cells dramatically reduces the stem cell populations and the resulting cell growth and spread that are hallmarks of cancer.

When they eliminated the DNMT1 gene in a breast-cancer mouse model, "The breast won't develop as well," Thangaraju said, but neither would about 80 percent of . The deletion even impacted super-aggressive, .

The findings point toward new therapeutic targets for breast cancer and potentially using blood levels of ISL1 as a way to diagnose early breast cancer, the researchers report. In fact, they've found that the anti-seizure medication valproic acid, already used in combination with chemotherapy to treat breast cancer, appears to increase ISL1 expression, which may help explain why the drug works for these patients, he said. The scientists are screening other small molecules that might work as well or better.

Mammary stem cells help maintain the breasts during puberty as well as pregnancy, both periods of dynamic breast cell growth. During pregnancy, breasts may generate 300 times more cells as they prepare for milk production. This mass production may also include tumor cells, a mutation that seems to increase with age, Thangaraju said. When the fetus is lost before term, immature cells that were destined to become breast cells, can more easily become cancer, said Rajneesh Pathania, a GRU graduate student and the study's first author.

DNMT1 is essential for maintaining a variety of stem cell types, such as , which produce all types of blood cells. But, its role in regulating the stem cells that make breast tissue and enable breast cancer has not been studied, the scientists write.

While the exact reasons remain unclear, there is an increased risk of breast cancer if the first pregnancy occurs after age 30 as well as in women who lose their baby during pregnancy or have an abortion. Women who never have children also are at increased risk, while multiple term pregnancies further decrease the risk, according to the American Cancer Society.

Theories include that the hormone-induced maturation of that occurs during pregnancy may increase the potential for breast cancer cells to be made as well. Also, most breast cancers thrive on estrogen and progesterone, which are both highly expressed during pregnancy and also help fuel stem cell growth.

During pregnancy, stem cells also make more of themselves so their population increases about five times. DNMT1 levels experience a similar increase.

In five different types of human breast cancer, researchers found high levels of DNMT1 and ISL1 turned off. Even in a laboratory dish, when they put the ISL1 gene back, human cells and stem cell activity were much reduced, Thangaraju said.

Explore further: Research finds target to prevent breast cancer relapse

Related Stories

Research finds target to prevent breast cancer relapse

April 23, 2015
Researchers have for the first time shown how a specific protein receptor on the surface of breast cells promotes the progression of breast cancer.

The switch that might tame the most aggressive of breast cancers

March 27, 2015
Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis ...

Molecular signature for outcomes of triple negative breast cancer

April 13, 2015
Compared to other types of breast cancer, triple negative breast cancers are often more aggressive and have fewer treatment options. In a new study published in the journal Proceedings of the National Academy of Sciences ...

Signalling protein plays different roles in breast cancer and normal cells

June 20, 2014
A key step in developing effective cancer therapies is identifying differences between normal, healthy cells and cancer cells – these differences can then be exploited to specifically kill tumour cells.

Recommended for you

Childhood stress leaves lasting mark on genes

July 18, 2018
Kids who experience severe stress are more likely to develop a host of physical and mental health problems by the time they reach adulthood, including anxiety, depression and mood disorders. But how does early life stress ...

Protein found to be key component in irregularly excited brain cells

July 17, 2018
In a new study in mice, researchers have identified a key protein involved in the irregular brain cell activity seen in autism spectrum disorders and epilepsy. The protein, p53, is well-known in cancer biology as a tumor ...

World's largest study on allergic rhinitis reveals new risk genes

July 17, 2018
An international team of scientists led by Helmholtz Zentrum München and University of Copenhagen has presented the largest study so far on allergic rhinitis in the journal Nature Genetics. The data of nearly 900,000 participants ...

New platform poised to be next generation of genetic medicines

July 16, 2018
A City of Hope scientist has discovered a gene-editing technology that could efficiently and accurately correct the genetic defects that underlie certain diseases, positioning the new tool as the basis for the next generation ...

Overcoming a major barrier to developing liquid biopsies

July 16, 2018
The idea of testing blood or urine to find markers that help diagnose or treat disease holds great promise. But as technology has improved to allow researchers to examine tiny fragments of RNA, one major problem has led to ...

Genetic marker for drug risk in multiple sclerosis offers path toward precision medicine

July 16, 2018
A team of researchers has uncovered a specific gene variant associated with an adverse drug reaction resulting in liver injury in a people with multiple sclerosis (MS). It is the first time researchers have been able to establish ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.